Satovsky Asset Management’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$451K Buy
3,239
+19
+0.6% +$2.66K 0.08% 37
2025
Q4
$395K Buy
3,220
+21
+0.7% +$2.55K 0.08% 37
2025
Q3
$355K Buy
3,199
+22
+0.7% +$2.5K 0.07% 39
2025
Q2
$352K Buy
3,177
+24
+0.8% +$2.55K 0.08% 33
2025
Q1
$353K Buy
3,153
+22
+0.7% +$2.27K 0.08% 34
2024
Q4
$289K Buy
3,131
+25
+0.8% +$2.25K 0.07% 34
2024
Q3
$260K Buy
3,106
+29
+0.9% +$2.21K 0.06% 42
2024
Q2
$211K Buy
3,077
+34
+1% +$2.27K 0.05% 47
2024
Q1
$223K Buy
3,043
+32
+1% +$2.46K 0.07% 44
2023
Q4
$244K Buy
3,011
+28
+0.9% +$2.18K 0.08% 40
2023
Q3
$224K Buy
2,983
+29
+1% +$2.23K 0.08% 37
2023
Q2
$228K Buy
2,954
+29
+1% +$2.31K 0.08% 38
2023
Q1
$243K Buy
2,925
+27
+0.9% +$2.24K 0.09% 34
2022
Q4
$249K Buy
+2,898
New +$229K 0.1% 34
2022
Q1
Sell
-2,774
Closed -$201K 41
2021
Q4
$201K Buy
+2,774
New +$191K 0.13% 32

Other funds holding GILD

Satovsky Asset Management's GILD Position: Q1 2026 in Review

Satovsky Asset Management increased its Gilead Sciences (GILD) stake by 0.59% in Q1 2026, buying an estimated $2.66K and bringing the position to 3,239 shares worth $451K. The position accounts for 0.08% of the portfolio, ranked #37.

Satovsky Asset Management first reported a position in GILD in Q4 2021 and has held it in 15 quarters since. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Satovsky Asset Management held 3,239 shares of Gilead Sciences worth $451K as of Q1 2026.
  • Satovsky Asset Management bought 19 Gilead Sciences shares in Q1 2026, an estimated $2.66K.
  • Gilead Sciences made up 0.08% of Satovsky Asset Management's portfolio in Q1 2026, its #37 holding.
  • Satovsky Asset Management first reported a position in Gilead Sciences in Q4 2021 and has held it in 15 quarters since.
  • 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Satovsky Asset Management's 13F filing for Q1 2026, filed 14 May 2026.